JL15003Injection
Preclinical
JL15003Injection is one of 7 therapeutic programs targeting Recurrent Glioblastoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
7 competitors in Recurrent Glioblastoma
#DrugCompanyPhaseTrials
1Tecentriq
RochePhase 2
Keytruda
Merck & Co.Phase 2
Avastin
RochePhase 2
Cabometyx
Bristol-Myers SquibbPreclinical
ACT001
NNationwide Children's Hospital
Phase 2
JL15003Injection
JJecho Biopharmaceuticals Co., Ltd.
Preclinical
LMP744
NNational Cancer Institute (NCI)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for JL15003Injection. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]